# Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer

> **NCT01872377** · NA · TERMINATED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 7 (actual)

## Conditions studied

- Pancreatic Carcinoma Non-resectable

## Interventions

- **RADIATION:** CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost

## Key facts

- **NCT ID:** NCT01872377
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2018-05-16
- **Final completion:** 2018-05-16
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** No longer recruiting patients to this study
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872377, "Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01872377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*